Polymorphisms at the microseminoprotein-β locus associated with physiologic variation in β-microseminoprotein and prostate-specific antigen levels

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 8, 2010, Pages 2035-2042

  Xu, Xing ^a   Valtonen André, Camilla ^b   Sävblom, Charlotta ^b   Halldén, Christer ^b   Lilja, Hans ^a,b   Klein, Robert J ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LUND UNIVERSITY   (Sweden)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA MICROSEMINOPROTEIN; BIOLOGICAL MARKER; KALLIKREIN; KALLIKREIN 2; MICROSEMINOPROTEIN BETA; PROSTATE ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BLOOD ANALYSIS; CANCER RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DETERMINATION; DNA POLYMORPHISM; GENE LOCUS; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SEMEN ANALYSIS;

ADOLESCENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; SEMEN; SWEDEN; TISSUE KALLIKREINS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77955434607     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0431     Document Type: Article

References (31)

1. Eeles R, Kote-Jarai Z, Giles G, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40: 316-21. (Pubitemid 351311772)
2. Thomas G, Jacobs K, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008;40:310-5. (Pubitemid 351311773)
3. Lilja H, Abrahamsson PA. Three predominant proteins secreted by the human prostate gland. Prostate 1988;12:29-38.
4. Weiber H, Andersson C, Murne A, et al. β Microseminoprotein is not a prostate-specific protein. Its identification in mucous glands and secretions. Am J Pathol 1990;137:593-603.
5. Abrahamsson PA, Andersson C, Bjork T, et al. Radioimmunoassay of β-microseminoprotein, a prostatic-secreted protein present in sera of both men and women. Clin Chem 1989;35:1497-503. (Pubitemid 19187853)
6. Ulvsbäck M, Lindström C, Weiber H, Abrahamsson PA, Lilja H, Lundwall A. Molecular cloning of a small prostate protein, known as β-microsemenoprotein, PSP94 or β-inhibin, and demonstration of transcripts in non-genital tissues. Biochem Biophys Res Commun 1989;164:1310-5. (Pubitemid 19283987)
7. Valtonen-André C, Sävblom C, Fernlund P, Lilja H, Giwercman A, Lundwall A. β-Microseminoprotein in serum correlates with the levels in seminal plasma of young, healthy males. J Androl 2008;29:330-7. (Pubitemid 351669022)
8. Tsurusaki T, Koji T, Sakai H, Kanetake H, Nakane P, Saito Y. Cellular expression of β-microseminoprotein (β-MSP) mRNA and its protein in untreated prostate cancer. Prostate 1998;35:109-16.
9. Vanaja D, Cheville J, Iturria S, Young C. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003;63:3877-82. (Pubitemid 36917897)
10. Hyakutake H, Sakai H, Yogi Y, et al. β-Microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinoma. Prostate 1993;22:347-55.
11. Garde SV, Basrur VS, Li L, et al. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate 1999;38:118-25.
12. Shukeir N, Arakelian A, Kadhim S, Garde S, Rabbani SA. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 2003;63:2072-8. (Pubitemid 36546186)
13. Nam R, Reeves J, Toi A, et al. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol 2006;175:1291-7.
14. Buckland PR, Hoogendoorn B, Coleman SL, Guy CA, Smith SK, O'Donovan MC. Strong bias in the location of functional promoter polymorphisms. Hum Mutat 2005;26:214-23.
15. Chang B-L, Cramer SD, Wiklund F, et al. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet 2009;18: 1368-75.
16. Xu B, Wang J, Tong N, et al. A functional polymorphism in MSMB gene promoter is associated with prostate cancer risk and serum MSMB expression. Prostate 2010;70:1146-52.
17. Wiklund F, Zheng SL, Sun J, et al. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate 2008;69:419-27.
18. Lilja H, Ulmert D, Vickers A. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008; 8:268-78. (Pubitemid 351430866)
19. Klein RJ, Halldén C, Cronin AM, et al. Blood biomarker levels to aid discovery of cancer-related single nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res 2010;3:611-9.
20. Richthoff J, Rylander L, Hagmar L, Malm J, Giwercman A. Higher sperm counts in Southern Sweden compared with Denmark. Hum Reprod 2002;17:2468-73.
21. Sävblom C, Malm J, Giwercman A, Nilsson JA, Berglund G, Lilja H. Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. Prostate 2005;65:66-72.
22. Elzanaty S, Richthoff J, Malm J, Giwercman A. The impact of epididymal and accessory sex gland function on sperm motility. Hum Reprod 2002;17:2904-11. (Pubitemid 35350909)
23. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for wholegenome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-75.
24. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21: 263-5. (Pubitemid 40202029)
25. Purcell S, Daly MJ, Sham PC. WHAP: haplotype-based association analysis. Bioinformatics 2007;23:255-6.
26. Waters KM, Stram DO, Le Marchand L, et al. A common prostate cancer risk variant 5′ of MSMB (microseminoprotein-β) is a strong predictor of circulating MSP (microseminoprotein) in multiple populations. Cancer Epidemiol Biomarkers Prev 2010. In press.
27. Lou H, Yeager M, Li H, et al. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A 2009; 106:7933-8.
28. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007;449:851-61.
29. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostatecancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
30. Andriole G, Crawford D, Grubb R, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310-9.
31. Zheng L, Sun J, Wiklund F, et al. Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Clin Cancer Res 2009;15:1105-11.